Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Robert "Bob" Swanson (1947–1999) was an American venture capitalist who co-founded Genentech in 1976 with Herbert Boyer. Genentech is one of the leading biotechnology companies in the world. He was CEO of Genentech from 1976 to 1990, and chairman from 1990 to 1996.
At the time of his retirement from the CDC, he was the centers' AIDS Advisor to the State of California and Special Consultant to Mayor Art Agnos in San Francisco. [9] In the latter capacity he served as the Chair of the Mayor's HIV Task Force. In 1993, Francis joined Genentech, Inc., of South San Francisco to try to develop a vaccine for HIV.
In 1976 Genentech, the first genetic engineering company was founded by Herbert Boyer and Robert Swanson and a year later the company produced a human protein (somatostatin) in E.coli. Genentech announced the production of genetically engineered human insulin in 1978. [75] In 1980 the U.S. Supreme Court in the Diamond v.
Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants -- First Medicine Approved to Treat Influenza in Infants Two Weeks of Age and Older -- SOUTH SAN FRANCISCO ...
Laura Perin, Napoleone Ferrara, and Matteo Garbelotto. Napoleone Ferrara (born 26 July 1956 in Catania) is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age ...
The dispute was launched by Novartis in a California state court but recently shifted to a federal court. The payments stemmed from a 2005 licensing agreement Genentech struck with then Chiron ...
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...